Kamada announced today that it will release financial results for the third quarter ended September 30, 2017, prior to the open of the U.S. financial markets on Monday, November 13.
Efficacy trend was demonstrated in the pre-determined subgroup of patients between the ages of 12 to 18, treated with the higher dose of 120mg/kg. The positive trend was observed in this age group for all three key efficacy measures of Type-1 Diabetes.
Listen to Kamada's CEO, Mr. Amir London, presenting the company's current commercial portfolio and significant growth, as well as the clinical pipeline and future value creating milestones. Link to audio file
Kamada announced that Gil Efron, Deputy Chief Executive Officer (Deputy CEO) & Chief Financial Officer (CFO) recently informed the Company of his plan to leave at the end of the year.
Kamada announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 3rd Annual Healthcare Conference.
Kamada announced today a collaboration for advanced research on Alpha-1 Antitrypsin (AAT) with a focus on mechanism of action with BGN Technologies (BGN), the business arm of Ben Gurion University (BGU). Professor Eli Lewis, Department of Clinical Biochemistry and Pharmacology at BGU, and one of the world's foremost AAT investigators, will lead the collaboration.
"This significant achievement for Kamada represents the second FDA approval for the Company," said Amir London, Kamada's Chief Executive Officer. "We are proud that our unique and advanced immune globulin purification technology was used in the development of KEDRAB, and look forward to a successful launch of the product with Kedrion Biopharma."
Kamada announced financial results for the three and six months ended June 30, 2017.
Kamada announced that it intends to offer and sell its ordinary shares in an underwritten public offering.
Kamada announced that it has priced its previously announced underwritten public offering of 3,333,334 of its ordinary shares at a price of $4.50 per share.